NCT05437692招募中2 期
A Prospective, Single Arm, Phase II Clinical Study on the Treatment of Locally Advanced Cervical Cancer (Ⅱ B to Ⅳ a) With Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy
Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2022年7月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
This is a prospective, single arm, phase II clinical study on the treatment of locally advanced cervical cancer (Ⅱ B to Ⅳ a) with Zimberelimab combined with concurrent radiotherapy and chemotherapy.
详细描述
This study will include 19 patients with locally advanced cervical cancer to explore the efficacy and safety of Zimberelimab in combination with concurrent radiotherapy for them.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •FIGO 2018 stage IIB to IVA cervical cancer;
- •Cervical squamous cell carcinoma, cervical adenocarcinoma or cervical adenosquamous carcinoma confirmed by histology;
- •Have not received any radiotherapy for cervical cancer in the past, and have not received immunotherapy;
- •Have measurable lesions (according to RECIST v1.1 standard);
- •ECOG score: 0 ~ 1;
- •18~75 years old (calculated on the day of signing the informed consent);
- •The estimated survival period exceeds 6 months;
- •Before enrollment, try to provide enough tumor tissue samples (archived or fresh biopsy samples) to evaluate and confirm the expression of PD-L1 and to detect other biomarkers; Considering the accessibility of clinical specimens, there is no mandatory requirement for specimens;
- •Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within ● months after the end of the study; Within 7 days before the study was enrolled, the serum or urine pregnancy test was negative, and must be non lactating patients;
- •For the full organ function defined in the protocol, the test samples must be collected within 7 days before the start of the study treatment;
- •The patients volunteered to join the study and signed the informed consent form.
排除标准
- •The subjects have other histological subtypes except those permitted by inclusion criteria 2;
- •Bilateral hydronephrosis, unless at least one side has been implanted with a stent or solved by a positioned nephrostomy;
- •Those who are allergic to gadolinium, a common non-ionic CT contrast agent and a magnetic resonance contrast agent
- •Have anatomical structure or tumor geometry or any other reasons or contraindications that cannot be treated with intracavitary brachytherapy or intracavitary and implantable brachytherapy;
- •Severe hypersensitivity (≥ grade 3) to cepalimumab and / or any of its excipients;
- •Participated in or had participated in clinical trials within 4 weeks before randomization;
- •Have been vaccinated or will be vaccinated with live vaccine within 30 days before the first study treatment;
- •Have received systemic immune stimulant, colony stimulating factor, interferon, interleukin and vaccine combination treatment within 6 weeks or 5 half lives (whichever is shorter) before the first administration;
- •Within 7 days before the first administration, the patient has been diagnosed with immune deficiency or is receiving chronic systemic steroid therapy (the dose exceeds 10mg prednisone equivalent per day) or any other form of immunosuppressive therapy;
- •Active autoimmune diseases requiring systemic treatment during the past two years (such as the use of disease regulating drugs, corticosteroids or immunosuppressive drugs);
- •Have a history of (non infectious) pneumonia requiring steroid treatment or currently have (non infectious) pneumonia;
- •Active infection requiring systematic treatment;
- •Known HIV infection history;
- •Known hepatitis B (defined as HBsAg reactivity) or known active hepatitis C virus (defined as detection of HCV RNA [qualitative]) infection history;
- •Known history of active tuberculosis (TB; Mycobacterium tuberculosis);
- •Received allogeneic tissue / solid organ transplantation;
- •Central nervous system metastasis such as tumor brain metastasis;
- •Patients with uncontrolled hydrothorax and ascites;
- •Patients with movement disorders such as pathological fractures caused by tumor bone metastasis;
- •Insufficient hematopoietic function of bone marrow (without blood transfusion within 14 days):
- •Abnormal liver:
- •Abnormal kidney:
- •Risk of bleeding:
- •Cardiovascular and cerebrovascular abnormalities:
研究组 & 干预措施
zimberelimab plus concurrent radiotherapy and chemotherapy
Experimental
19 patients will treated with zimberelimab plus concurrent radiotherapy and chemotherapy
干预措施: zimberelimab combined With concurrent radiotherapy and chemotherapy (Drug)
结局指标
主要结局
ORR
时间窗: one year
Objective response rate based on RECIST v1.1
次要结局
- OS(three years)
- adverse events(two years)
- DCR(one year)
- PFS(two years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerNon-small Cell Lung CancerNCT06734182Guangdong Provincial People's Hospital25
尚未招募
2 期
IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Esophageal Squamous Cell Carcinoma (ESCC)PD-1 InhibitorsNCT06078657The First Affiliated Hospital of Zhengzhou University46
尚未招募
2 期
First-line Replacement Maintenance of Envafolimab in Advanced NSCLCNon-Small-Cell LungNCT05465733First Affiliated Hospital Xi'an Jiaotong University25
尚未招募
2 期
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.NMIBCNCT06630871Fujian Medical University Union Hospital40
招募中
2 期
A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass NodulesProgressionNCT04905056Shanghai Zhongshan Hospital120